كندا - الإنجليزية - Health Canada

marcan pharmaceuticals inc - busulfan - solution - 60mg - busulfan 60mg - antineoplastic agents

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - busulfan -

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

esp pharma, inc. - busulfan (unii: g1ln9045dk) (busulfan - unii:g1ln9045dk) - injection - 60 mg in 10 ml - busulfex® (busulfan) injection is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. busulfex is contraindicated in patients with a history of hypersensitivity to any of its components.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

otsuka australia pharmaceutical pty ltd - busulfan, quantity: 60 mg - injection - excipient ingredients: dimethylacetamide; macrogol 400 - busulfex is indicated for use in combination with cyclophosphamide, melphalan or fludarabine in conditioning prior to haematopoietic stem cell transplantation.

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

nexus pharmaceuticals llc - busulfan (unii: g1ln9045dk) (busulfan - unii:g1ln9045dk) - busulfan is indicated for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia. busulfan is contraindicated in patients with a history of hypersensitivity to any of its components. risk summary busulfan can cause fetal harm when administered to a pregnant woman based on animal data. busulfan was teratogenic in mice, rats, and rabbits following administration during organogenesis. the solvent, dma, may also cause fetal harm when administered to a pregnant woman. in rats, dma doses of approximately 40% of the daily dose of dma in the busulfan dose on a mg/m2 basis given during organogenesis caused significant developmental anomalies (see data ). there are no available human data informing the drug-associated risk. advise pregnant women of the potential risk to a fetus. the background risk of major birth defects and miscarriage for the indicated populations are unknown. however, the background risk

إسرائيل - الإنجليزية - Ministry of Health

tzamal bio-pharma ltd - busulfan - solution for injection - busulfan 60 mg / 10 ml - busulfan - busulfan - for use in combination with other chemotherapeutic agents and/or radiotherapy as a conditioning regimen prior to hematopoietic progenitor cell transplantation.

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

woodward pharma services llc - busulfan (unii: g1ln9045dk) (busulfan - unii:g1ln9045dk) - myleran (busulfan) is indicated for the palliative treatment of chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia. myleran is contraindicated in patients in whom a definitive diagnosis of chronic myelogenous leukemia has not been firmly established. myleran is contraindicated in patients who have previously suffered a hypersensitivity reaction to busulfan or any other component of the preparation.

الولايات المتحدة - الإنجليزية - NLM (National Library of Medicine)

waylis therapeutics llc - busulfan (unii: g1ln9045dk) (busulfan - unii:g1ln9045dk) - myleran (busulfan) is indicated for the palliative treatment of chronic myelogenous (myeloid, myelocytic, granulocytic) leukemia. myleran is contraindicated in patients in whom a definitive diagnosis of chronic myelogenous leukemia has not been firmly established. myleran is contraindicated in patients who have previously suffered a hypersensitivity reaction to busulfan or any other component of the preparation.

ماليزيا - الإنجليزية - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

fresenius kabi malaysia sdn. bhd - busulfan -

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - busulfan, quantity: 2 mg - tablet, film coated - excipient ingredients: pregelatinised maize starch; magnesium stearate; lactose; titanium dioxide; hypromellose; triacetin - indications as at 10 february 2005: treatment of chronic granulocytic leukaemia. it has been shown to be superior to splenic irradiation when judged by survival times, control of spleen size and maintenance of haemoglobin levels. although not curative, busulfan reduces the total granulocyte mass, relieves disease symptoms and improves the clinical state of the patient. busulfan is not useful once blast transformation has occurred. busulfan produces prolonged remission in polycythaemia vera. it is especially useful in cases resistant to radiophosphorus (32 p) and where there is marked thrombocytosis. busulfan is useful in selected cases of essential thrombocythaemia and myelofibrosis.